OKYO Pharma Ltd

LSE:OKYO

OKYO Pharma Ltd operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. The Company’s principal activity is to develop drugs for inflammatory dry eye diseases and chronic pain by targeting G protein-coupled receptors (GPCRs). The GPCRs is the family of membrane proteins involved in many biological processes. GPCRs is used for the treatment of various conditions, including cardiovascular disease, cancer, and diabetes. Its product pipeline includes OK-101 for Dry Eye Disease (DED), OK-101 for Non-ophthalmic Indications, and OK-201 to treat corneal neuropathic pain. The OK-101 is its lead preclinical product candidate, which is focused on keratoconjunctivitis sicca commonly known as DED which is a multifactorial disease caused by an underlying inflammation resulting in the lack of lubrication and moisture in the surface of the eye. The OK-201 is a non-opioid analgesic for ocular pain management without side effects and the potential abuse associated with opioid medications.